Profile data is unavailable for this security.
About the company
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. The Company calls its solution The Vivos Method. The Vivos Method represents the first clinically effective nonsurgical, noninvasive and nonpharmaceutical solution for treating mild to severe OSA. The Vivos Method includes treatment regimens that employ the proprietary Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and other modalities that alter the size, shape and position of the soft tissues that comprise a patient's upper airway and/or palate. The Vivos Method comprises various products and services, including Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, and Vivos Airway Intelligence Service.
- Revenue in USD (TTM)13.36m
- Net income in USD-15.64m
- Incorporated2020
- Employees114.00
- LocationVivos Therapeutics Inc7921 Southpark Plaza,, Suite 210LITTLETON 80120United StatesUSA
- Fax+1 (302) 655-5049
- Websitehttps://vivos.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pressure Biosciences Inc | 2.27m | -29.56m | 4.47m | 15.00 | -- | -- | -- | 1.97 | -1.70 | -1.70 | 0.1299 | -1.22 | 1.02 | 2.28 | 9.17 | 151,505.30 | -1,074.63 | -643.54 | -- | -- | 6.89 | 34.75 | -1,050.30 | -798.21 | 0.0185 | -0.4182 | -- | -- | -13.64 | -5.05 | 21.52 | -- | -34.47 | -- |
| Guided Therapeutics Inc | 82.00k | -3.23m | 4.48m | 4.00 | -- | -- | -- | 54.67 | -0.0623 | -0.0623 | 0.0016 | -0.0721 | 0.0374 | 0.0904 | 11.71 | 20,500.00 | -137.80 | -136.13 | -- | -- | 32.93 | 29.39 | -3,685.37 | -3,666.67 | 0.1138 | -11.13 | -- | -- | 653.85 | 11.45 | 24.40 | -- | -- | -- |
| ADM Tronics Unlimited Inc | 2.85m | -716.86k | 4.74m | 7.00 | -- | 4.30 | -- | 1.67 | -0.0106 | -0.0106 | 0.0421 | 0.0163 | 0.9772 | 3.85 | 4.25 | -- | -24.62 | -11.45 | -38.81 | -15.77 | 38.45 | 43.73 | -25.19 | -15.28 | 1.24 | -- | 0.2902 | -- | 14.66 | -0.4159 | 93.04 | -- | -- | -- |
| Avinger Inc | 7.62m | -16.13m | 5.02m | 68.00 | -- | -- | -- | 0.6587 | -18.16 | -18.16 | 7.49 | -2.56 | 0.4084 | 1.20 | 6.38 | 112,102.90 | -102.83 | -70.93 | -- | -131.57 | 22.43 | 30.87 | -251.78 | -208.91 | 0.4764 | -10.02 | 1.38 | -- | -7.51 | -0.6736 | 32.76 | -- | -24.21 | -- |
| Hawkeye Systems Inc | 0.00 | -804.18k | 5.09m | 44.00 | -- | -- | -- | -- | -0.1186 | -0.1186 | 0.00 | -0.29 | 0.00 | -- | -- | -- | -66.07 | -330.11 | -- | -- | -- | -- | -- | -218.49 | -- | -2.78 | 10.45 | -- | -- | -- | 4.85 | -- | -- | -- |
| Vapotherm Inc | 70.07m | -54.94m | 5.22m | 182.00 | -- | -- | -- | 0.0745 | -8.62 | -8.62 | 11.00 | -11.02 | 0.8122 | 1.46 | 7.53 | 385,011.00 | -63.68 | -49.73 | -587.27 | -62.54 | 45.28 | 43.56 | -78.40 | -78.99 | 0.1259 | -1.27 | 2.59 | -- | 2.80 | 10.14 | 48.62 | -- | -10.38 | -- |
| Encision Inc | 6.87m | -448.00k | 5.88m | 31.00 | -- | 2.68 | -- | 0.857 | -0.0381 | -0.0381 | 0.5835 | 0.1863 | 1.64 | 1.96 | 7.84 | 221,520.00 | -10.69 | -1.07 | -14.05 | -1.46 | 50.54 | 52.27 | -6.52 | -0.613 | 1.08 | -6.22 | 0.1123 | -- | -4.17 | -3.44 | -393.90 | -- | 12.89 | -- |
| Fuse Medical Inc | 18.40m | 3.63m | 6.06m | 31.00 | 2.28 | -- | 1.64 | 0.3295 | 0.036 | 0.036 | 0.2307 | -0.0031 | 0.9593 | 0.7018 | 5.75 | 593,671.90 | 18.91 | 0.7504 | 48.45 | 1.35 | 64.95 | 54.98 | 19.72 | 0.6552 | 0.3143 | -1.13 | 1.12 | -- | -8.67 | -6.72 | 295.11 | 34.66 | -- | -- |
| Sonendo Inc | 40.19m | -57.74m | 6.36m | 216.00 | -- | 0.259 | -- | 0.1581 | -0.6125 | -0.5552 | 0.426 | 0.3482 | 0.4448 | 2.07 | 7.58 | 186,055.60 | -63.91 | -- | -78.82 | -- | 27.64 | -- | -143.67 | -- | 2.14 | -10.83 | 0.4695 | -- | 5.30 | -- | -6.78 | -- | -- | -- |
| BIOLASE Inc | 49.16m | -37.62m | 6.41m | 157.00 | -- | -- | -- | 0.1304 | -37.97 | -37.97 | 38.54 | 0.5726 | 1.34 | 2.38 | 8.68 | 313,146.50 | -56.30 | -49.28 | -115.21 | -85.80 | 34.02 | 35.27 | -41.97 | -50.72 | 0.683 | -6.61 | 0.8778 | -- | 1.45 | 1.27 | -30.39 | -- | 18.63 | -- |
| Sigyn Therapeutics Inc | 0.00 | -3.56m | 6.43m | 5.00 | -- | -- | -- | -- | -3.04 | -3.04 | 0.00 | -3.28 | 0.00 | -- | -- | 0.00 | -724.37 | -493.15 | -- | -- | -- | -- | -- | -10,223.96 | 0.0199 | -1.92 | -- | -- | -- | -- | -41.51 | -- | -- | -- |
| Arch Therapeutics Inc | 130.55k | -8.43m | 6.58m | 8.00 | -- | -- | -- | 50.38 | -3.68 | -3.68 | 0.0425 | -2.45 | 0.0833 | 0.0637 | -- | 16,318.75 | -538.25 | -188.28 | -- | -804.63 | 33.37 | -- | -6,458.14 | -26,945.92 | 0.0164 | -1.27 | -- | -- | 383.83 | -- | -32.35 | -- | -21.76 | -- |
| Predictive Oncology Inc | 1.96m | -14.78m | 6.69m | 34.00 | -- | 1.63 | -- | 3.41 | -3.66 | -3.66 | 0.4853 | 0.9977 | 0.1099 | 1.71 | 4.95 | 57,642.65 | -82.89 | -91.80 | -108.54 | -126.29 | 64.18 | 64.64 | -754.19 | -1,419.99 | 1.35 | -- | 0.0093 | -- | 18.24 | 4.75 | 45.67 | -- | 5.44 | -- |
| Vivos Therapeutics Inc | 13.36m | -15.64m | 6.87m | 114.00 | -- | 10.00 | -- | 0.5144 | -11.00 | -11.00 | 8.73 | 0.2131 | 0.9247 | -- | 31.59 | 117,219.30 | -108.24 | -89.72 | -243.30 | -149.70 | 58.90 | 70.20 | -117.06 | -113.15 | -- | -- | 0.00 | -- | -13.87 | 29.48 | 43.04 | -- | -8.48 | -- |
| Neurometrix Inc | 5.27m | -7.98m | 7.72m | 26.00 | -- | 0.4068 | -- | 1.47 | -6.32 | -6.32 | 4.20 | 9.44 | 0.2381 | 1.25 | 10.08 | 202,700.40 | -36.07 | -23.24 | -38.94 | -27.26 | 61.97 | 59.17 | -151.51 | -48.88 | 10.11 | -- | 0.00 | -- | -28.52 | -18.18 | -47.84 | -- | 5.03 | -- |
| Nexalin Technology Inc | 158.86k | -4.94m | 8.55m | 6.00 | -- | 3.68 | -- | 53.83 | -0.6676 | -0.6676 | 0.0215 | 0.3129 | 0.0363 | 0.1778 | 44.01 | 26,476.67 | -112.76 | -- | -139.94 | -- | 82.54 | -- | -3,110.58 | -- | 4.75 | -- | 0.00 | -- | -91.62 | -- | -173.80 | -- | -- | -- |
Data as of May 23 2024. Currency figures normalised to Vivos Therapeutics Inc's reporting currency: US Dollar USD
9.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Strategic Wealth Designers LLCas of 31 Dec 2023 | 128.79k | 4.72% |
| Armistice Capital LLCas of 31 Mar 2024 | 103.58k | 3.79% |
| Commonwealth Equity Services LLCas of 31 Mar 2024 | 15.00k | 0.55% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 10.58k | 0.39% |
| CA Indosuez Gestion SAas of 31 Mar 2024 | 2.37k | 0.09% |
| Newbridge Financial Services Group, Inc.as of 31 Mar 2024 | 1.95k | 0.07% |
| Tower Research Capital LLCas of 31 Mar 2024 | 1.73k | 0.06% |
| SignatureFD LLCas of 31 Mar 2024 | 547.00 | 0.02% |
| Group One Trading LPas of 31 Mar 2024 | 228.00 | 0.01% |
| Thrivent Trust Co.as of 31 Mar 2024 | 160.00 | 0.01% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
